Kinome-wide screening of HER2+ breast cancer cells for molecules that mediate cell proliferation or sensitize cells to trastuzumab therapy.
about
Development of a test that measures real-time HER2 signaling function in live breast cancer cell lines and primary cells.A functional signal profiling test for identifying a subset of HER2-negative breast cancers with abnormally amplified HER2 signaling activity.MPZL1 forms a signalling complex with GRB2 adaptor and PTPN11 phosphatase in HER2-positive breast cancer cellsCrosstalk between NRF2 and HIPK2 shapes cytoprotective responses.Integrative kinome profiling identifies mTORC1/2 inhibition as treatment strategy in ovarian clear cell carcinoma.Association Analysis of Somatic Copy Number Alteration Burden With Breast Cancer Survival
P2860
Kinome-wide screening of HER2+ breast cancer cells for molecules that mediate cell proliferation or sensitize cells to trastuzumab therapy.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Kinome-wide screening of HER2+ ...... cells to trastuzumab therapy.
@en
Kinome-wide screening of HER2+ ...... cells to trastuzumab therapy.
@nl
type
label
Kinome-wide screening of HER2+ ...... cells to trastuzumab therapy.
@en
Kinome-wide screening of HER2+ ...... cells to trastuzumab therapy.
@nl
prefLabel
Kinome-wide screening of HER2+ ...... cells to trastuzumab therapy.
@en
Kinome-wide screening of HER2+ ...... cells to trastuzumab therapy.
@nl
P2093
P2860
P356
P1433
P1476
Kinome-wide screening of HER2+ ...... cells to trastuzumab therapy.
@en
P2093
P2860
P2888
P356
10.1038/ONCSIS.2014.45
P577
2014-12-15T00:00:00Z
P5875
P6179
1015194351